Core Insights - IceCure Medical has received approval from Swissmedic for the ProSense® system, expanding its global market access following recent FDA authorization for low-risk breast cancer treatment [1] Company Developments - The ProSense® system and cryoprobes are now officially registered for the treatment of malignant or benign tissue in various organs, including the breast, lung, liver, kidney, and musculoskeletal system [1] - This approval supports IceCure's commercial momentum and enhances its position in the minimally-invasive cryoablation technology market [1]

Core Insights - IceCure Medical Ltd. will release its financial and operational results for the nine months ended September 30, 2025, on November 19, 2025, before the Nasdaq Stock Market opens [1] - A conference call to discuss these results and other corporate developments is scheduled for the same day at 10:00 a.m. EST [2] Company Overview - IceCure Medical specializes in developing and marketing advanced liquid-nitrogen-based cryoablation therapy systems aimed at destroying both benign and cancerous tumors through freezing [2] - The company's primary focus areas include breast, kidney, bone, and lung cancer, with its flagship ProSense® system marketed globally [2] Upcoming Events - The conference call will be accessible via a live webcast, and a recording will be available afterward on the company's investor relations website [2]

Core Insights - IceCure Medical Ltd. has promoted Shay Levav to Chief Operating Officer to enhance operational effectiveness and capitalize on the commercial momentum following FDA marketing clearance for ProSense® [1][2] - ProSense® is the first FDA-authorized device for local treatment of early-stage, low-risk breast cancer, specifically for women aged 70 and above [3][4] - The ProSense® system utilizes liquid nitrogen for cryoablation, offering a minimally invasive alternative to surgical tumor removal, with applications in various cancers [4][6] Company Developments - The appointment of Shay Levav is expected to strengthen IceCure's operational foundation as the company expands its presence in the U.S. market [2] - Levav has been instrumental in the clinical and regulatory processes for ProSense® and will continue to oversee Regulatory Affairs, Quality Assurance, and Clinical Affairs in his new role [1][2] Product Overview - ProSense® enhances patient care by accelerating recovery, reducing pain, and minimizing surgical risks, making it suitable for office-based procedures [5] - The system is designed for the treatment of benign and cancerous lesions in various organs, including the breast, kidney, lung, and liver [4][6]

Core Insights - IceCure Medical's Cryoablation System combined with stereotactic body radiation therapy (SBRT) shows a 5-year overall survival (OS) rate of 74%, significantly higher than the 41% - 52% OS rates reported for SBRT alone [1][6] - The study indicates that the combination therapy yields 5-year OS outcomes comparable to surgical options, which have an OS rate of 67% - 82% [1][6] - Lung cancer remains the most diagnosed cancer globally, with an incidence of 2.5 million cases, and is the leading cause of cancer-related deaths [1][5] Study Details - The independent study evaluated the effectiveness of combining SBRT with cryoablation for stage I non-small cell lung cancer (NSCLC) tumors measuring 2 cm [2] - A total of 64 patients with a mean tumor diameter of 2.7 cm were treated, with a median follow-up duration of 74 months [2][6] - The study was led by Dr. Hiroaki Nomori and involved multiple institutions in Japan [1][2] Results Summary - The 5-year local control rate was reported at 93% [6] - The 3-year disease-specific survival rate was 96%, and the 5-year disease-specific survival rate was 92% [6] - No treatment-related mortality was observed, although the most frequent complication post-cryoablation was pneumothorax, occurring in 40% of cases [6] Market Implications - The results of this study may significantly impact major markets, including the U.S. and Europe, by providing a minimally invasive treatment option for inoperable stage I NSCLC patients [2] - IceCure Medical's ProSense® system is positioned as a safe and effective alternative to surgical tumor removal, enhancing patient recovery and reducing complications [10][9]

Core Insights - The FDA granted marketing authorization for ProSense® for the local treatment of low-risk breast cancer in patients aged 70 and above, following the TME Fall Summit, which is expected to enhance commercial traction due to significant interest from key opinion leaders [2][5]. Company Overview - IceCure Medical Ltd. specializes in minimally-invasive cryoablation technology, which destroys tumors by freezing, providing an alternative to surgical tumor removal [1][8]. - The ProSense® Cryoablation System is the first and only device authorized by the FDA for treating low-risk breast cancer in specific patient demographics, including those unsuitable for surgery [5][6]. Event Participation - IceCure participated in the TME Take the Lead in Breast Cancer Care Fall Summit, which gathered over 40 key opinion leaders to discuss advancements in breast cancer care, particularly focusing on de-escalation strategies and minimally invasive options [1][2]. Clinical Engagement - The company received high interest during a cryoablation faculty session led by Dr. Richard Fine, a prominent investigator in the ICE3 trial, which is the largest cryoablation study in the U.S. [3][4]. - The TME summit highlighted the growing relevance of cryoablation in breast oncology treatment planning, indicating a shift towards less invasive treatment options [2][3]. Product Features - ProSense® utilizes liquid nitrogen to create large lethal zones for effective tumor destruction, enhancing patient recovery by reducing pain and surgical risks [6][7]. - The system is designed for easy transport and can facilitate fast, office-based procedures for breast tumors, making it a convenient option for both patients and providers [7][8].

Core Points - IceCure Medical has received U.S. FDA marketing authorization for ProSense Cryoablation for the local treatment of low-risk breast cancer in women aged 70 and above when combined with Endocrine Therapy [3] Group 1 - The conference call was held to discuss the FDA's marketing authorization for ProSense Cryoablation [3] - Participants in the call included IceCure Medical's CEO Eyal Shamir and VP of Sales, North America, Shad Good [3] - The company believes that ProSense will be the only Cryoablation System approved in the U.S. for early-stage breast cancer in the foreseeable future [5]

Core Viewpoint - IceCure Medical has received U.S. FDA marketing authorization for ProSense Cryoablation for the local treatment of low-risk breast cancer in women aged 70 and above when combined with Endocrine Therapy [3]. Company Summary - IceCure Medical's ProSense Cryoablation is now the only Cryoablation System approved in the U.S. for early-stage breast cancer, positioning it to potentially set a new standard of care for the appropriate patient population [5]. - The conference call included participation from IceCure Medical's CEO Eyal Shamir and VP of Sales, North America, Shad Good, indicating a strong leadership presence in discussing the implications of this authorization [3]. Industry Summary - The marketing authorization from the FDA is a significant milestone for the industry, as it highlights advancements in treatment options for low-risk breast cancer, particularly for older women [3]. - The approval may influence future treatment protocols and standards of care within the oncology sector, especially concerning cryoablation technologies [5].

Core Insights - IceCure Medical (ICCM) has received FDA marketing authorization for its ProSense cryoablation system, the first minimally invasive treatment for low-risk breast cancer in women aged 70 and above, positioning it as an alternative to lumpectomy [1][8] - The approval opens commercial opportunities in the U.S. and validates IceCure's leadership in cryoablation technology, with established reimbursement pathways enhancing adoption prospects [2][4] Company Summary - Following the FDA announcement, ICCM shares rose by 12% in after-market trading, although the stock has seen a year-to-date decline of 12.4% compared to the industry’s 5.2% growth and the S&P 500's 15.2% gain [3] - ICCM's market capitalization stands at $66.2 million, with an expected earnings growth of 26.7% in 2025 [5] Competitive Position - The FDA authorization significantly enhances IceCure's commercial outlook by granting access to the U.S. breast cancer treatment market, establishing a competitive moat against rivals who will face higher clinical data requirements for entry [4][10] - ProSense benefits from a CPT III reimbursement code covering $3,800 of facility costs, with potential for expanded coverage as adoption increases, positioning IceCure for accelerated revenue growth and market penetration [10] Clinical Validation - The FDA's decision was supported by robust clinical data from the ICE3 trial, demonstrating outcomes comparable to traditional surgical methods while offering a quicker, minimally invasive procedure [9] - IceCure plans to conduct a post-market study involving around 400 patients across 30 sites in the U.S. to further validate long-term efficacy, which will also serve as commercial centers for efficient rollout [9] Industry Outlook - The global cryoablation for cancer market was valued at $3.5 billion in 2024 and is projected to grow at a CAGR of 6.1%, reaching $5.8 billion by 2033, driven by rising cancer incidence and an aging population [11][12] - The increasing adoption of cryoablation for smaller tumors is a major driver of market expansion, as it offers fewer side effects compared to traditional treatments [12]

Summary of IceCure Medical's Conference Call Company and Industry - **Company**: IceCure Medical Ltd - **Industry**: Medical Devices, specifically focused on breast cancer treatment Core Points and Arguments 1. **FDA Marketing Authorization**: IceCure Medical received FDA marketing authorization for the ProSense cryoablation system for local treatment of low-risk breast cancer in women aged 70 and above when combined with endocrine therapy [2][6] 2. **Target Population**: The approved indication covers approximately 46,000 women in the U.S. annually, specifically those with biologically low-risk tumors up to 1.5 centimeters who are not suitable for surgery [6][7] 3. **Innovative Treatment**: ProSense is the first and only medical device approved for breast cancer treatment that offers a minimally invasive outpatient procedure, which destroys tumors by freezing without removing breast tissue [7][8] 4. **Clinical Validation**: The FDA's decision was supported by data from the ICE3 study, showing outcomes comparable to traditional lumpectomy without surgery [7][10] 5. **Market Positioning**: The marketing authorization positions ProSense to set a new standard of care for eligible patient populations in the U.S. and reflects IceCure's commitment to improving women's quality of life globally [3][8] 6. **Reimbursement Strategy**: Procedures conducted through the post-market study will be eligible for CPT III reimbursement, which covers $3,800 of facility costs, potentially accelerating adoption across the U.S. [10][4] 7. **Global Expansion**: The FDA authorization is expected to have a global impact, facilitating regulatory submissions in other countries, including Japan and the European Union [11][12] Additional Important Content 1. **Post-Market Surveillance Study**: IceCure plans to conduct a post-market study involving approximately 400 patients across 30 sites, which will also serve as commercial sites for treatment [10][17] 2. **Future Capital Needs**: The company successfully raised $10 million in a rights offering to fund short-term commercialization and the post-market study [31] 3. **Go-to-Market Strategy**: IceCure's strategy includes expanding the U.S. sales team in 2026 and engaging with professional medical societies to ensure cryoablation is included in treatment guidelines [9][34] 4. **Potential for Off-Label Use**: Physicians may treat patients under 70 as off-label, particularly those who are non-candidates for surgery due to comorbidities [36][37] 5. **Upcoming Events**: The CFO will meet investors in Los Angeles and attend the Maxim Growth Conference in New York City later in October [39]

Core Insights - The FDA has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for early-stage low-risk breast cancer, marking a significant innovation in breast cancer treatment [1] - ProSense® offers a non-surgical option that destroys tumors by freezing, providing efficacy and safety comparable to standard lumpectomy, along with excellent cosmetic results and high patient satisfaction [1] - The treatment is specifically indicated for women aged 70 and over, with an estimated annual patient population of 46,000 in the U.S. [1] Company Overview - IceCure Medical Ltd. is the developer of the ProSense® technology, which represents the first new innovation in local treatment for early-stage breast cancer in decades [1] - The company is publicly traded on Nasdaq under the ticker ICCM [1] - A conference call is scheduled for October 6, 2025, to discuss the implications of this FDA authorization [1]